Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher
Rallybio Corporation RLYB shares are trading higher after the company announced a collaboration with Johnson & Johnson JNJ to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is a rare immune…#rallybiocorporation #johnsonjohnsonjnj #fnait #rallybio #johnsonjohnson #johnsonjohnsons #phase2 (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2024 Category: Consumer Health News Source Type: news
Clinical Takeaways in Thrombocytopenia From ASH 2023 Clinical Takeaways in Thrombocytopenia From ASH 2023
Clinical takeaways in immune thrombocytopenia (ITP) from ASH 2023 include efficacy of novel therapies, infection risk in chronic ITP, and ITP effects during pregnancy, as reported by Dr Howard Liebman.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2024 Category: Consumer Health News Tags: Internal Medicine ReCAP Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia More Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia
Medscape_Education_No_Bots (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2023 Category: Consumer Health News Tags: Roundtable Source Type: news
Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
FRIDAY, Oct. 6, 2023 -- The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2023 Category: Pharmaceuticals Source Type: news
Thrombocytopenia associated with elemental mercury poisoning in two siblings - Connecticut, July 2022 - Hogeland EW, Somers TS, Yip L, Doyon S, Redlich CA, Orsey AD, Woda CB, Swan ST, Feder HMJ.
Two siblings aged 5 and 15 years from Connecticut were hospitalized with petechial rash, oral mucositis, and severe thrombocytopenia approximately 10 days after they played with a jar of elemental mercury they found in their home. Before the mercury exposu... (Source: SafetyLit)
Source: SafetyLit - September 25, 2023 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news
Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings - Connecticut, July 2022
This report describes two cases of thrombocytopenia in siblings after elemental mercury vapor exposure. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 21, 2023 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Source Type: news
Adenovirus May Trigger Thrombocytopenia, Thrombosis, Case Studies Suggest
(MedPage Today) -- In rare cases, symptomatic human adenovirus infection may trigger a life-threatening prothrombotic anti-platelet factor 4 (PF4) disorder resembling vaccine-induced immune thrombotic thrombocytopenia (VITT), according to a report... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 9, 2023 Category: Cardiology Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Media News - July 11, 2023 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphomaApproval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is given for a fixed period of time and made to be readily available, providing patients with a treatment end date and treatment-free periodBasel, 11 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) ha...
Source: Roche Investor Update - July 11, 2023 Category: Pharmaceuticals Source Type: news
Study Weighs Timing of Platelet Transfusion With Central Venous Catheter Placement
FRIDAY, May 26, 2023 -- For patients with severe thrombocytopenia, withholding of prophylactic platelet transfusion before ultrasound-guided placement of a central venous catheter (CVC) results in more CVC-related bleeding events than prophylactic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2023 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
CHMP recommends EU approval of Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved,Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase I/II NP30179 study, whereColumvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is part of Roche ’s industry-leading CD20xCD3 T-cell-engaging bispecific developmentprogramme, which aims to transform the treatment experience for people with blood cancers using off-the-shelf and fixed-duration optionsBasel, 26 ...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved,Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase I/II NP30179 study, whereColumvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is part of Roche ’s industry-leading CD20xCD3 T-cell-engaging bispecific developmentprogramme, which aims to transform the treatment experience for people with blood cancers using off-the-shelf and fixed-duration optionsBasel, 26 ...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
